Related Experiment Video
Updated: Apr 27, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Perspective-weight loss, obstructive sleep apnea therapy, or both for cardiometabolic risk in obesity-related
Brandon Nokes1,2, Brian S Wojeck3, Christopher N Schmickl2
1Department of Medicine, Sleep Medicine Section, VA San Diego Healthcare System, San Diego, CA, United States.
Abstract:
The emergence of potent and durable obesity pharmacotherapies has the potential to drastically alter the treatment landscape for comorbid obesity and obstructive sleep apnea. Recent clinical trials examining the impact of weight loss on obstructive sleep apnea have demonstrated marked improvements in both weight and obstructive sleep apnea severity, leading to the first Food and Drug Administration approval of a weight loss medication for obstructive sleep apnea. However, several questions remain unanswered regarding which trial and management strategies will best optimize real-world outcomes for patients with comorbid obesity and obstructive sleep apnea in an equitable manner.
Insights
New obesity medications show promise for treating obstructive sleep apnea (OSA). Weight loss significantly improves OSA severity, but optimal real-world strategies for comorbid obesity and OSA require further investigation.
Area of Science:
- Medical Science
- Pharmacology
- Sleep Medicine
Background:
- Obesity and obstructive sleep apnea (OSA) frequently coexist.
- Emerging pharmacotherapies for obesity offer new treatment avenues.
Purpose of the Study:
- To review the impact of weight loss pharmacotherapies on OSA.
- To identify optimal management strategies for comorbid obesity and OSA.
Main Methods:
- Review of recent clinical trials on weight loss and OSA.
- Analysis of FDA approvals for weight loss medications in OSA treatment.
Main Results:
- Weight loss medications demonstrate significant improvements in weight and OSA severity.
- First FDA approval granted for a weight loss medication specifically for OSA.
Conclusions:
- Pharmacotherapies represent a significant advancement in managing comorbid obesity and OSA.
- Further research is needed to determine equitable and effective real-world treatment protocols.
More Related Videos
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Heart Failure VI: Adjunct Therapies
Obesity
COPD: Management Using Bronchodilators and Corticosteroids
Atherosclerosis III: Management
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

